View Item 

Show simple item record

Some Recent Developments in the Pharmacology of Heparin

dc.contributor.authorCoon, William W.en_US
dc.date.accessioned2013-04-08T20:49:55Z
dc.date.available2013-04-08T20:49:55Z
dc.date.issued1979-07en_US
dc.identifier.citationCoon, William W. (1979). "Some Recent Developments in the Pharmacology of Heparin." The Journal of Clinical Pharmacology 19(7). <http://hdl.handle.net/2027.42/97239>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97239
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleSome Recent Developments in the Pharmacology of Heparinen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Surgery, Section of General Surgery, University of Michigan Medical Center, 1405 E. Ann Street, Ann Arbor, Mich. 48109.en_US
dc.identifier.pmid479378en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97239/1/j.1552-4604.1979.tb02490.x.pdf
dc.identifier.doi10.1002/j.1552-4604.1979.tb02490.xen_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceGardner, B.: Experiences with the use of intracholedochal heparinized saline for the treatment of retained common duct stones. Ann. Surg. 177: 240 ( 1973 ).en_US
dc.identifier.citedreferenceWarlow, C., Beattie, A. G., Terry, G., Ogston, D., Kenmure, A. C. F., and Douglas, A. S.: A double blind trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis after myocardial infarction. Lancet 1: 934 ( 1974 ).en_US
dc.identifier.citedreferenceGallus, A. S., Hirsh, J., O'Brien, S. E., McBride, J. A., Tuttle, R. J., and Gent, M.: Prevention of venous thromboembolism with small subcutaneous doses of heparin. J.A.M.A. 235: 198 ( 1976 ).en_US
dc.identifier.citedreferenceInternational Multicentre Trial: Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 2: 45 ( 1975 ).en_US
dc.identifier.citedreferenceSagar, S., Massey, J., and Sanderson, J. M.: Low‐dose heparin in prophylaxis against fatal pulmonary embolism. Brit. Med. J. 4: 257 ( 1975 ).en_US
dc.identifier.citedreferenceHeatley, R. V., Hughes, L. E., Morgan, A., and Okwonga, W.: Preoperative or postoperative deep vein thrombosis. Lancet 1: 437 ( 1976 ).en_US
dc.identifier.citedreferenceCoon, W. W.: Epidemiology of venous thromboembolism. Ann. Surg. 186: 149 ( 1977 ).en_US
dc.identifier.citedreferenceGrode, G. A., Anderson, S. J., Grotta, H. M., and Falb, R. D.: Non‐thrombogenic materials via a simple coating process. Trans. Amer. Soc. Artif. Int. Organs 15: 1 ( 1969 ).en_US
dc.identifier.citedreferenceChawla, A. S., and Chang, T. M. S.: Non‐thrombogenic surface by radiation grafting of heparin: preparation, in vitro and in vivo studies. Biomater. Med. Devices Artif. Organs 2: 157 ( 1974 ).en_US
dc.identifier.citedreferenceSalzman, E. W., Merrill, E. W., Binder, A., Wolf, C. F. W., Ashford, T. P., and Austen, W. G.: Protein—platelet interaction on heparinized surfaces. J. Biomed. Mater. Res. 3: 69 ( 1969 ).en_US
dc.identifier.citedreferenceRembaum, A., Yen, S. P. S., Ingram, M., Newton, J. F., and Hu, C. L.: Platelet adhesion to heparin‐bonded and heparin‐free surfaces, Biomater. Med. Devices Artif. Organs 1: 99 ( 1973 ).en_US
dc.identifier.citedreferenceJacobsson, B., and Schlossman, D.: Thrombogenic properties of heparinized vascular catheters. Acta Radiol. 14: 569 ( 1973 ).en_US
dc.identifier.citedreferenceDudley, B., Williams, J. L., Able, K., and Muller, B.: Synthesis and characterization of blood compatible surfaces. Dynamic tube test applied to heparinized surfaces. Trans. Amer. Soc. Artif. Int. Organs 22: 538 ( 1976 ).en_US
dc.identifier.citedreferenceGentry, P. W., and Alexander, B.: Specific coagulation factor absorption to insoluble heparin. Biochem. Biophys. Res. Commun. 50: 500 ( 1973 ).en_US
dc.identifier.citedreferenceBrenner, W. I., Engelman, R. M., Williams, C. D., Boyd, A. D., and Reed, G. E.: Non‐thrombogenic aortic and vena caval bypass using heparin‐coated tubes. Amer. J. Surg. 127: 555 ( 1974 ).en_US
dc.identifier.citedreferenceGott, V. L.: Wall‐bonded heparin—historical background and current clinical applications. Advan. Exp. Med. Biol. 52: 351 ( 1975 ).en_US
dc.identifier.citedreferenceHawkins, I. F., and Kelly, M. J.: Benzalkonium‐heparin‐coated angiographic catheters. Radiology 109: 589 ( 1973 ).en_US
dc.identifier.citedreferenceMcDuffie, N. M., Dietrich, C. P., and Nader, H. B.: Electrofocusing of heparin‐fractionation of heparin into 21 components distinguishable from other acidic mucopolysaccharides. Biopolymers 14: 1473 ( 1975 ).en_US
dc.identifier.citedreferencePerlin, A. S., Mackie, D. M., and Dietrich, C. P.: Evidence of 1–4 linked 4‐O‐α‐l‐idopyranosyluronic acid (2‐sulfate)‐ 2‐deoxy‐2‐sulfamino‐d‐glycopyranolsyl (6‐sulfate) sequence in heparin. Carbohydr. Res. 18: 185 ( 1971 ).en_US
dc.identifier.citedreferenceSilvan, M. E., and Dietrich, C. P.: Structure of heparin. J. Biol. Chem. 250: 6841 ( 1975 ).en_US
dc.identifier.citedreferenceNader, H. B., McDuffie, N. M., and Dietrich, C. P.: Heparin fractionation by electrofocusing: presence of 21 components of different molecular weights. Biochem. Biophys. Res. Commun. 57: 488 ( 1974 ).en_US
dc.identifier.citedreferenceJaques, L. B., and Kavanaugh, L. W.: Variability of heparin preparations in clinical use. Thromb. Haemostas. Suppl. 56: 171 ( 1973 ).en_US
dc.identifier.citedreferenceCifonelli, J. A.: The relationship of molecular weight and sulfate content and distribution to anticoagulant activity of heparin preparations. Carbohydr. Res. 37: 145 ( 1974 ).en_US
dc.identifier.citedreferenceDanishefsky, I.: Synthesis and properties of heparin derivatives. Advan. Exp. Med. Biol. 52: 105 ( 1975 ).en_US
dc.identifier.citedreferenceJorpes, J. E., Bostrom, H., and Mutt, V.: The linkage of the amino group in heparin. J. Biol. Chem. 183: 607 ( 1950 ).en_US
dc.identifier.citedreferenceKiss, J.: Chemical structure of heparin. In Heparin: Chemistry and Clinical Usage, Kakkar, V. V., and Thomas, D. P., Eds. New York, Academic Press, 1976, p. 3.en_US
dc.identifier.citedreferenceHöök, M., Björk, I., Hopwood, J., and Lindahl, U.: Anticoagulant activity of heparin: separation of high‐activity and low activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett. 66: 90 ( 1976 ).en_US
dc.identifier.citedreferenceLam, L. H., Silbert, J. E., and Rosenberg, R. D.: The separation of active and inactive forms of heparin. Biochem. Biophys. Res. Commun. 69: 570 ( 1976 ).en_US
dc.identifier.citedreferenceBangham, D. R., and Woodward, P. M.: A collaborative study of heparins from different sources. Bull. WHO 42: 129 ( 1970 ).en_US
dc.identifier.citedreferenceKuo, S. H., Jaques, L. B., and Millar, G. I.: An improved in vivo procedure for standardization of heparin preparations. J. Pharm. Pharmacol. 24: 858 ( 1972 ).en_US
dc.identifier.citedreferenceBaltes, B. J., Diamond, S., and D'Agostino, R. J.: Comparison of anticoagulant activity of two preparations of purified heparin. Clin. Pharmacol. Therap. 14: 287 ( 1973 ).en_US
dc.identifier.citedreferenceGomez‐Perez, F.: Anticoagulant activity of two commercially available heparin preparations. A controlled study. J. Clin. Pharmacol. 12: 413 ( 1972 ).en_US
dc.identifier.citedreferenceMcMahon, F. G., Jain, A. K., Ryan, J. R., and Lefton, T. E.: Anticoagulant potency of mucosal and lung heparin. Clin. Pharmacol. Therap. 17: 79 ( 1975 ).en_US
dc.identifier.citedreferenceBell, W. R.: Thrombocytopenia occurring during heparin therapy. New England J. Med. 295: 276 ( 1976 ).en_US
dc.identifier.citedreferenceBell, W. R., Tomasulo, P. A., Alving, B. M., and Duffy, T. P.: Thrombocytopenia occurring during the administration of heparin: a prospective trial in 52 patients. Ann. Int. Med. 85: 155 ( 1976 ).en_US
dc.identifier.citedreferenceJaques, L. B.: Standardization of heparin for clinical use. Lancet 1: 287 ( 1975 ).en_US
dc.identifier.citedreferenceWindsor, E., and Freeman, L.: An investigation of routes of administration of heparin other than injection. Amer. J. Med. 37: 408 ( 1964 ).en_US
dc.identifier.citedreferenceLasker, S. E.: Low‐molecular‐weight derivative of heparin that is orally active in mice. Advan. Exp. Med. Biol. 52: 119 ( 1975 ).en_US
dc.identifier.citedreferenceJaques, L. V., Mahadoo, J., and Kavanaugh, L. W.: Intrapulmonary heparin. A new procedure for anticoagulant therapy. Lancet 2: 1157 ( 1976 ).en_US
dc.identifier.citedreferenceThomas, D. P., Sagar, S., Stomatakis, J. D., Maffei, F. H. A., Erdi, A., and Kakkar, V. V.: Plasma heparin levels after administration of calcium and sodium salts of heparin. Thromb. Res. 9: 241 ( 1976 ).en_US
dc.identifier.citedreferenceWhitehead, M. I., and McCarthy, T. G.: A comparative trial of subcutaneous sodium and calcium heparin as assessed by local hematoma formation and pain. In Heparin: Chemistry and Clinical Use, Kakkar, V. V., and Thomas, D. P., Eds. New York, Academic Press, 1976, p. 361.en_US
dc.identifier.citedreferenceBergquist, D., and Hallbook, T.: Are there any differences in thrombosis prophylaxis and side‐effects between sodium and calcium heparin? Proc. Sixth International Congress on Thrombosis and Haemostasis, Bala Cynwyd, Pa., June 26‐July 2, 1977. Thromb. Haemostas. 38 ( 1 ): 106 ( 1977 ).en_US
dc.identifier.citedreferenceEstes, J. W.: The fate of heparin in the body. Curr. Therap. Res. 18: 45 ( 1975 ).en_US
dc.identifier.citedreferenceJaques, L. B., Mahadoo, J., and Riley, J. F.: The mast cell/heparin paradox. Lancet 1: 411 ( 1977 ).en_US
dc.identifier.citedreferenceEssien, E. M., Kinlough‐Rathbone, R., Moore, S., and Mustard, J. F.: The role of heparin on the inhibition of platelet adhesion to damaged arterial endothelial surfaces. Thromb. Haemostas. 34: 600 ( 1975 ) (Abstr.).en_US
dc.identifier.citedreferenceHiebert, L. M., and Jaques, L. B.: The observation of heparin on endothelium after injection. Thromb. Res. 8: 195 ( 1976 ).en_US
dc.identifier.citedreferenceLi, E. H. H., Fenton, J. W., II, and Feinman, R. D.: The role of heparin in the thrombin — antithrombin III reaction. Arch. Biochem. Biophys. 175: 153 ( 1976 ).en_US
dc.identifier.citedreferenceBjörk, I., and Nordenman, B.: Acceleration of the reaction between thrombin and antithrombin III by non‐stoichiometric amounts of heparin, Europ. J. Biochem. 68: 507 ( 1976 ).en_US
dc.identifier.citedreferenceStead, N., Kaplan, A. P., and Rosenberg, R. D.: Inhibition of activated factor XII by antithrombin—heparin cofactor. J. Biol. Chem. 251: 6481 ( 1976 ).en_US
dc.identifier.citedreferenceDamus, P. S., Hicks, M., and Rosenberg, R. D.: Anticoagulant action of heparin. Nature 246: 355 ( 1973 ).en_US
dc.identifier.citedreferenceYin, E. T., Wessler, S., and Stoll, P. J.: Identity of plasma‐activated factor X inhibitor with antithrombin III and heparin cofactor. J. Biol. Chem. 246: 3712 ( 1971 ).en_US
dc.identifier.citedreferenceRosenberg, J. S., McKenna, P. W., and Rosenberg, R. D.: Inhibition of human factor IXa by human antithrombin. J. Biol. Chem. 250: 8883 ( 1975 ).en_US
dc.identifier.citedreferenceBurrowes, C. E., Habal, F. M., and Movat, H. Z.: The inhibition of human plasma kallikrein by antithrombin III. Thromb. Res. 7: 175 ( 1975 ).en_US
dc.identifier.citedreferenceHighsmith, R. F., and Rosenberg, R. D.: The inhibition of human plasmin by human antithrombin‐heparin cofactor. J. Biol. Chem. 249: 4335 ( 1974 ).en_US
dc.identifier.citedreferenceGodal, J. C., Rygh, M., and Laake, K.: Progressive inactivation of purified factor VII by heparin and antithrombin in. Thromb. Res. 5: 773 ( 1974 ).en_US
dc.identifier.citedreferenceMarciniak, E., Farley, C. H., and DeSimone, P. A.: Familial thrombosis due to antithrombin III deficiency. Blood 43: 219 ( 1974 ).en_US
dc.identifier.citedreferenceHan, P., and Ardlie, N. G.: Heparin, platelets and blood coagulation: implications for low‐dose heparin prophylactic regimens in venous thrombosis. Brit. J. Haematol. 27: 253 ( 1974 ).en_US
dc.identifier.citedreferenceGregorius, F. K., and Rand, R. W.: Scanning electron microscopic observations of the common carotid artery of the rat. III. Heparin effect on platelets. Surgery 79: 584 ( 1976 ).en_US
dc.identifier.citedreferenceKwaan, H. C., and Hatem, A.: Effect of lung and gut heparin on experimental arterial thrombosis. Advan. Exp. Biol. Med. 52: 263 ( 1975 ).en_US
dc.identifier.citedreferenceEika, C.: The platelet‐aggregating effect of eight commercial heparins. Scand. J. Haematol. 9: 480 ( 1972 ).en_US
dc.identifier.citedreferenceSakamoto, S., Sakamoto, M., Goldhaber, P., and Glimcher, M. J.: Studies on the interaction between heparin and mouse bone collagenase. Biochem. Biophys. Acta 395: 41 ( 1975 ).en_US
dc.identifier.citedreferenceLenaers‐Claeys, G., and Vaes, G.: Conditions governing the release of collagenase and procollagenase by bone explants in culture: effects of heparin. Arch. Int. Physiol. Biochim. 84: 634 ( 1976 ).en_US
dc.identifier.citedreferenceBabcock, R. B., Dumper, C. W., and Scharfman, W. B.: Heparin‐induced immune thrombocytopenia. New England J. Med. 295: 237 ( 1976 ).en_US
dc.identifier.citedreferenceDavey, M. G., and Lander, H.: Effect of injected heparin upon platelet levels in man. J. Clin. Pathol. 21: 55 ( 1968 ).en_US
dc.identifier.citedreferenceCoon, W. W., and Willis, P. W.: Hemorrhagic complications of anticoagulant therapy. Arch. Int. Med. 133: 386 ( 1974 ).en_US
dc.identifier.citedreferenceJick, H., Slone, D., Borda, I., and Shapiro, S.: Efficacy and toxicity of heparin in relation to age and sex. New England J. Med. 279: 284 ( 1968 ).en_US
dc.identifier.citedreferenceJaques, L. B.: Stress and multiple‐factor etiology of bleeding. Ann. New York Acad. Sci. 115: 78 ( 1964 ).en_US
dc.identifier.citedreferenceSlone, D., Jick, H., Lewis, G. P., Shapiro, S., and Miettinen, O. S.: Intravenously given ethacrynic acid and gastrointestinal bleeding. J.A.M.A. 209: 1668 ( 1969 ).en_US
dc.identifier.citedreferenceGlazier, R. L., and Crowell, E. B.: Randomized prospective trial of continuous versus intermittent heparin therapy. J.A.M.A. 236: 1365 ( 1976 ).en_US
dc.identifier.citedreferenceSalzman, E. W., Deykin, D., Shapiro, R. M., and Rosenberg, R. D.: Management of heparin therapy; controlled prospective trial. New England J. Med. 292: 1042 ( 1975 ).en_US
dc.identifier.citedreferenceChiu, H. M., Hirsh, J., Yung, W. L., Rogoeczi, E., and Gent, M.: Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 49: 171 ( 1977 ).en_US
dc.identifier.citedreferenceMant, M. J., O'Brien, B. D., Thong, K. L., Hammand, G. W., Birtwhistle, R. U., and Grace, M. G.: Hemorrhagic complications of heparin therapy. Lancet 1: 1133 ( 1977 ).en_US
dc.identifier.citedreferenceGenton, E.: Guidelines for heparin therapy. Ann. Int. Med. 80: 77 ( 1974 ).en_US
dc.identifier.citedreferenceSilver, D.: Pulmonary embolism: prevention, detection and non‐operative management, Surg. Clin. North Amer. 54: 1089 ( 1974 ).en_US
dc.identifier.citedreferenceGurewich, V., Cohen, M., and Thomas, D. P.: Humoral factors in massive pulmonary embolism. Amer. Heart J. 76: 784 ( 1968 ).en_US
dc.identifier.citedreferenceThomas, D. P.: Therapeutic role of heparin in acute pulmonary embolism. Curr. Therap. Res. 18: 21 ( 1975 ).en_US
dc.identifier.citedreferenceHirsh, J., Van Aken, W. G., Gallus, A. S., Dollery, C. T., Cade, J. F., and Yung, W. L.: Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 53: 691 ( 1976 ).en_US
dc.identifier.citedreferenceSoloway, H. B., Cornett, B. M., and Grayson, J. W., Jr.: Comparison of various activated partial thromboplastin reagents on the laboratory control of heparin therapy. Amer. J. Clin. Pathol. 59: 587 ( 1973 ).en_US
dc.identifier.citedreferenceTeien, A. N., and Abildgaard, U.: On the value of the activated partial thromboplastin time (APTT) in monitoring heparin therapy. Thromb. Haemostas. 35: 592 ( 1976 ).en_US
dc.identifier.citedreferencePenner, J. A.: Experience with a thrombin clotting time assay for measuring heparin activity. Amer. J. Clin. Pathol. 61: 645 ( 1974 ).en_US
dc.identifier.citedreferenceDenson, K. W. E., and Bonnar, J.: The measurement of heparin. A method based upon the potentiation of anti‐factor Xa. Thromb. Haemostas. 30: 471 ( 1973 ).en_US
dc.identifier.citedreferenceYin, E. T., Wessler, W., and Butler, J. V.: Plasma heparin: a unique, practical, submicrogram‐sensitive assay. J. Lab. Clin. Med. 81: 298 ( 1973 ).en_US
dc.identifier.citedreferenceGrann, V. R., Homewood, K., and Golden, W.: Polybrene neutralization as a rapid means of monitoring blood heparin levels. Amer. J. Clin. Pathol. 58: 26 ( 1972 ).en_US
dc.identifier.citedreferenceTeien, A. M., and Lie, M.: Heparin assay in vitro: a comparison of five clotting assays. Thromb. Res. 7: 777 ( 1975 ).en_US
dc.identifier.citedreferenceCongdon, J. E., Kardinal, C. G., and Wallin, J. D.: Monitoring heparin therapy in hemodialysis. J.A.M.A. 226: 1529 ( 1973 ).en_US
dc.identifier.citedreferenceJaberi, M., Bell, W. R., and Benson, D. W.: Control of heparin therapy in open heart surgery. J. Thorac. Cardiovasc. Surg. 67: 133 ( 1974 ).en_US
dc.identifier.citedreferenceGoodman, T. L., Todd, M. E., and Goldsmithy E. I.: Laboratory observations and clinical implications of monitoring the effect of heparin by bioassay. Surg. Gynecol. Obstet. 142: 673 ( 1976 ).en_US
dc.identifier.citedreferenceZucker, S., and Cathey, M. H.: Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effect of heparin. J. Lab. Clin. Med. 73: 320 ( 1969 ).en_US
dc.identifier.citedreferenceBasu, D., Gallus, A., Hirsh, J., and Cade, J.: A prospective study of the value of monitoring heparin treatment with activated partial thromboplastin time. New England J. Med. 287: 324 ( 1972 ).en_US
dc.identifier.citedreferenceCoon, W. W., and Willis, P. W., III: Recurrence of venous thromboembolism. Surgery 73: 823 ( 1973 ).en_US
dc.identifier.citedreferenceBrown, W. V., Shaw, W., Baginsky, M., Boberg, J., and Augustin, J.: Lipases and lipoprotein. In Lipoprotein Metabolism, Greten, H., Ed. Berlin, Springer‐Verlag, 1976, p. 2.en_US
dc.identifier.citedreferenceOlivecrona, T., Bengtsson, G., Marklund, S. E., Lindahl, U., and Höök, M.: Heparin—lipoprotein lipase interactions. Fed. Proc. 36: 60 ( 1977 ).en_US
dc.identifier.citedreferenceCoon, W. W., and Willis, P. W., 3rd: Some side effects of heparin, heparinoids and their antagonists. Clin. Pharmacol. Therap. 7: 379 ( 1966 ).en_US
dc.identifier.citedreferenceOstrowitz, A., and Gardner, B.: Studies of bile as a suspending medium and its relationship to gallstone formation. Surgery 68: 329 ( 1970 ).en_US
dc.identifier.citedreferenceMok, H. Y. I., Bell, G. D., Whitney, B., and Dowling, R. H.: Stones in common bile duct: non‐operative management. Proc. Roy. Soc. Med. 67: 658 ( 1974 ).en_US
dc.identifier.citedreferencePatterson, H. C.: Heparin as a resolvent agent of residual common duct stones. Gastroenterology 64: 781 ( 1973 ) (Abstr.).en_US
dc.identifier.citedreferenceCatt, P. B., Hogg, D. F., Clunie, G. J. A., and Hardie, I. R.: Retained biliary calculi: removal by a simple non‐operative technique. Ann. Surg. 180: 247 ( 1974 ).en_US
dc.identifier.citedreferenceSharnoff, J. G.: Results in the prophylaxis of postoperative thromboembolism. Surg. Gynecol. Obstet. 123: 303 ( 1966 ).en_US
dc.identifier.citedreferenceWessler, S.: Prevention of venous thromboembolism by low‐dose heparin. Mod. Concepts Cardiovasc. Dis. 45: 105 ( 1976 ).en_US
dc.identifier.citedreferenceKakkar, V. V.: The current status of low‐dose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism. World J. Surg. 2: 3 ( 1978 ).en_US
dc.identifier.citedreferenceGallus, A. S., Hirsh, J., Tuttle, R. J., Trebilcock, R., O'Brien, S. E., Carroll, J. J., Minden, J. H., and Hudecki, S. M.: Small subcutaneous doses of heparin in prevention of venous thrombosis. New England J. Med. 288: 551 ( 1973 ).en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1552-4604.1979.tb02490.x.pdf
Size:
1.839MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.